Medtelligence: Linking Science to Clinical Practice - Medtelligence

Medtelligence Hero

Linking Science
to Clinical Practice

Innovative, high-quality medical education for clinicians in cardiology and other specialties.

Featured

Inside the IgAN Clinic: Shared Decision-Making Into Practice
Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CE
Inside the IgAN Clinic: Shared Decision-Making Into Practice
0.25 credits
- Jonathan Barratt, MD, PhD
0.25 credits
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
CME/CE
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
0.25 credits
- Ellie Kelepouris, MD, FACP, FAHA
- Nihar R. Desai, MD, MPH
0.25 credits
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
CME/CE
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
0.25 credits
- Steven Fishbane, MD
- Maurizio Gallieni, MD
0.25 credits
MinuteCE®
FSGS 360°: From Patient Experience to Precision Medicine
1.00 credit 9 episodes
- Kenneth Lieberman, MD
- Meghan Sise, MD
- Vladimir Tesar
1.00 credit 9 episodes

Popular

Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
CME/CE
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
CME/CE
Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source
0.25 credits
- Richard Lafayette, MD, FACP
- Ankana Daga, MD
0.25 credits
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Cardiology
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
- Florian Rader, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CE
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
MinuteCE®
Redefining oHCM Care: Efficacy and Safety of Myosin Inhibitors
1.00 program credit
- Michael Nassif, MD, MSc
- Anjali Owens, MD
1.00 program credit
Molecular Precision: How Myosin Inhibitors Redefine Control
Molecular Precision: How Myosin Inhibitors Redefine Control
MinuteCE®
Molecular Precision: How Myosin Inhibitors Redefine Control
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
MinuteCE®
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
1.00 program credit
- Ahmad Masri, MD, MS
- Anjali Owens, MD
1.00 program credit
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
CME/CE In-Person Event
Translating Evidence Into Practice: Patient-Centered, Guideline-Driven Care in ANCA-Associated Vasculitis
June 04, 2026
Glasgow
1.00 credit